457 related articles for article (PubMed ID: 7656540)
1. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin.
Tapson VF; Hull RD
Clin Chest Med; 1995 Jun; 16(2):281-94. PubMed ID: 7656540
[TBL] [Abstract][Full Text] [Related]
2. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
3. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
4. Low molecular weight heparin: a critical analysis of clinical trials.
Green D; Hirsh J; Heit J; Prins M; Davidson B; Lensing AW
Pharmacol Rev; 1994 Mar; 46(1):89-109. PubMed ID: 8190751
[TBL] [Abstract][Full Text] [Related]
5. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
6. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
7. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
[TBL] [Abstract][Full Text] [Related]
8. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
Kamphuisen PW; Agnelli G
Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients.
Haas S
Semin Thromb Hemost; 1999; 25 Suppl 3():101-5. PubMed ID: 10549724
[TBL] [Abstract][Full Text] [Related]
11. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
Whang PG; Lieberman JR
Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
[TBL] [Abstract][Full Text] [Related]
12. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials.
Wein L; Wein S; Haas SJ; Shaw J; Krum H
Arch Intern Med; 2007 Jul; 167(14):1476-86. PubMed ID: 17646601
[TBL] [Abstract][Full Text] [Related]
14. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
Bergmann JF; Neuhart E
Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
[TBL] [Abstract][Full Text] [Related]
15. The rationale for long-term prophylaxis of venous thromboembolism.
Agnelli G; Mancini GB; Biagini D
Orthopedics; 2000 Jun; 23(6 Suppl):s643-6. PubMed ID: 10875429
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic indications of low molecular weight heparins].
Samama MM; Michaut-Paterno F
Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941
[TBL] [Abstract][Full Text] [Related]
17. [Low molecular weight heparin: favorable effect profile for prevention and therapy of venous thrombosis].
Marbet GA
Ther Umsch; 1992 Dec; 49(12):843-9. PubMed ID: 1336627
[TBL] [Abstract][Full Text] [Related]
18. Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery.
Bergqvist D
Br J Surg; 2004 Aug; 91(8):965-74. PubMed ID: 15286956
[TBL] [Abstract][Full Text] [Related]
19. [Low molecular weight heparin versus unfractionated heparin in the treatment of deep venous thrombosis--a meta-analysis].
Nielsen JD; Landorph A
Ugeskr Laeger; 1994 Oct; 156(40):5844-9. PubMed ID: 7985276
[TBL] [Abstract][Full Text] [Related]
20. Treatment of symptomatic venous thromboembolism: improving outcomes.
Büller HR
Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():41-8. PubMed ID: 12073179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
